Developed a urine test to predict the aggressiveness of prostate cancer and decide how to treat it in a personalised way. The result is due to scientists from the University of East Anglia, Norfolk and Norwich University Hospital and was presented in the BJU International journal. 

Prostate cancer is very common but just as often it is not aggressive and may not be treated without putting the patient’s life at risk. However, to date, tests are lacking to understand which of the patients who have received a diagnosis of this tumor are actually to be treated and which are not. 

For this purpose, the experts have developed an urine test that is read by artificial intelligence: the test examines the activity of genes in the urine sample to discern between an aggressive and non-aggressive cancer.

Depending on the active genes the test understands if there is a tumor and if it is to be treated, recognising even such low-risk formations as to have a probability up to eight times lower than needing therapies five years after diagnosis.

This research shows that the urine test could be used not only to diagnose the tumor without an invasive biopsy, but also to identify the individual patient’s risk level. This would mean being able to predict whether the patient has or will need therapies.